Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

• News Releases

• Gilead-Sciences-to-Release-Second-Quarter-2026-Financial-Results-on-Tuesday-August-4-2026

Share Article

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2026 financial results and guidance will be released on Tuesday, August 4, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s second quarter 2026 financial results and provide a business update.

A live webcast will be available in the Investors section ofwww.gilead.comand will be archived there for one year.

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company’s website atwww.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Jacquie Ross, CFA – Investorsinvestor_relations@gilead.com

Share Article

Some of the content on this page is not intended for users outside the U.S.

• Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026July 21, 2026

• Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral TherapyJuly 21, 2026

• Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and CureJuly 21, 2026

• U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast CancerJune 24, 2026

• European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 InhibitorsJune 23, 2026

• U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV PreventionJune 15, 2026

Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy

Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure

U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer

European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors

U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention